WO2015050366A1 - 사르코신 대사산물 중 포름알데히드 또는 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단 방법 - Google Patents
사르코신 대사산물 중 포름알데히드 또는 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단 방법 Download PDFInfo
- Publication number
- WO2015050366A1 WO2015050366A1 PCT/KR2014/009215 KR2014009215W WO2015050366A1 WO 2015050366 A1 WO2015050366 A1 WO 2015050366A1 KR 2014009215 W KR2014009215 W KR 2014009215W WO 2015050366 A1 WO2015050366 A1 WO 2015050366A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostate cancer
- test paper
- sarcosine
- diagnostic test
- cancer diagnostic
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/9065—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on CH-NH groups of donors (1.5)
- G01N2333/90672—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on CH-NH groups of donors (1.5) with oxygen as acceptor (1.5.3) in general
- G01N2333/90677—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on CH-NH groups of donors (1.5) with oxygen as acceptor (1.5.3) in general with a definite EC number (1.5.3.-)
- G01N2333/90683—Sarcosine oxidase (1.5.3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
Definitions
- the present invention relates to a prostate cancer diagnostic test paper and a method for diagnosing prostate cancer using the same, and in particular, a test paper for diagnosing prostate cancer using formaldehyde or peroxide, which is produced by oxidizing sarcosine contained in the urine of a prostate cancer patient, and using the same It is characterized by providing a method for diagnosing prostate cancer.
- prostate cancer is the sixth most common cancer in men after lung cancer, stomach cancer, liver cancer, colon cancer, and esophageal cancer. It is one of the most commonly diagnosed cancers among men dying 97,000, but it is difficult to track the development of the disease.
- a typical diagnosis relies on a blood test to find a specific protein called Prostate Specific Antigen (PSA) in the blood followed by a biopsy.
- PSA Prostate Specific Antigen
- prostate-specific antibodies are often elevated in prostate cancer, this does not indicate the presence of a direct tumor, and the high levels of antibodies do not mean their malignancy.
- the presence of trace amounts of prostate-specific antibodies in the blood of healthy men has been a reason to lower the reliability of prostate cancer diagnosis through prostate-specific antibody tests.
- concentration of sarcosine a methylated form of the amino acid glycine
- the existing prostate cancer diagnostic means and some prior arts related to the method are as follows.
- the invention described in Japanese Laid-Open Patent Application (2012-529021), filed on June 2, 2010 by Charite Universitats Kunststoff Berlin, is an ex vivo method for diagnosing prostate cancer or its predisposition. Measuring at least one metabolite of only a test sample of a subject suspected of having it and diagnosing prostate cancer or its predisposition by the at least one metabolite.
- the preceding patents include the collection of metabolites, data collection including characteristic values of metabolites, and storage media including the data collection.
- the prior art also provides a system for comparing the characteristic values of the metabolite of the sample, which is connected in a form capable of operating with the data storage medium. It also includes the use of one metabolite to prepare a diagnostic means comprising at least one metabolite and a diagnostic means for diagnosing prostate cancer.
- This prior art relates to a method of classifying metabolites related to prostate cancer, and it is described that the sarcosine content is measured to diagnose prostate cancer.
- LC liquid chromatography
- GC gas chromatography
- the present invention is different in that it provides a prostate cancer diagnostic test paper using formaldehyde, a sarcosine metabolite, and a prostate cancer diagnostic method using the same.
- the invention relating to "a colorimetric measurement method and reagent of a sample by enzymatic oxidation" (registered number 1992-0001449), filed and filed in South Korea on August 9, 1989, by Boehringer Mannheim GmbH.
- the method for measuring the colorimetric measurement of a sample by enzymatic oxidation of the sample in the presence and the amount of the sample the method of measuring the electron acceptor reduced by color formation, the oxidation step between +1 and -1 as a direct electron acceptor
- It relates to a colorimetric measurement method of a sample by enzymatic oxidation of the sample, characterized in that the sample is oxidized by an appropriate redox enzyme in the presence of a substance selected from the group of compounds having nitrogen.
- the preceding invention is different from the present invention using sarcosine oxidase because it uses glucose oxidoreductase, and although a colorimetric measuring method is described for measuring the sample amount, it does not basically use a sarcosine metabolite. There is a difference from the present invention in that it does not.
- the invention regarding a method for diagnosing and treating preeclampsia or eclampsia discloses a compound for increasing the concentration of VEGF or PlGF or
- the present invention relates to a method for treating preeclampsia or eclampsia using a compound that reduces the sF1t-1 concentration. It also features a method of monitoring preeclampsia or preeclampsia by detecting sF1t-1, VEGF, or PlGF levels. Also characterized by a method of diagnosing preeclampsia or eclampsia by detecting sF1t-1, VEGF, or PlGF levels in a subject.
- the present invention uses sarcosine oxidase to detect sarcosine content for prostate cancer diagnosis.
- the configuration is different, the use of colorimetric assays for the diagnosis of disease is somewhat similar, but the present invention differs in that it uses colorimetric assays for detecting formaldehyde produced by sarcosine oxidation.
- the invention relating to the metabolic profiling method of prostate cancer (Japanese Patent Laid-Open No. 2010-537170), filed by Metaboton, Inc. on August 15, 2008, relates to a cancer marker, in particular, ideally present in prostate cancer. Metabolites are provided, and diagnostic, research, and therapeutic uses are targeted to cancer-specific metabolites.
- the preceding invention is somewhat similar in that it is described in terms of measuring sarcosine content for diagnosing prostate cancer, but differs from the present invention in that it does not describe the use of sarcosine oxidase to measure sarcosine content, urine GC-MS (Gas Chromatography / Mass Spectrometry) and UHPLC-MS (Ultra High Performance Liquid Chromatography Mass Spectrometry) are used to determine the sarcosine content of the present invention, whereas the present invention uses formaldehyde produced by sarcosine oxidation. It is different in that it uses a colorimetric test paper to detect.
- the present invention has been proposed to solve the above-mentioned conventional problems, and an object of the present invention is to qualitatively and quantify sarcosine in urine. By visually confirming the visual acuity, it is to provide a test paper and a method for diagnosing prostate cancer without specialists and expensive equipment.
- prostate cancer diagnostic test paper using formaldehyde which is a sarcosine metabolite according to the technical idea of the present invention, a manufacturing method thereof, and a prostate cancer diagnostic method using the same, sarcosine for generating a sarcosine metabolite Sarcosine Oxidase; And 4-amino-3-hydrazino-5-mercapto-1,2,4-triazole (AHMT: 4-Amino-3-hydrazino, which functions as a color source by reacting with formaldehyde produced by oxidation of sarcosine). -5-mercapto-1,2,4-triazole);
- AHMT 4-amino-3-hydrazino, which functions as a color source by reacting with formaldehyde produced by oxidation of sarcosine.
- a prostate cancer diagnostic test paper comprising a.
- N-methylbenzothiazolion-2-hydrazone N-methylbenzothiszolinone-2-hydrazone
- a prostate cancer diagnostic test paper comprising a.
- sarcosine oxidase that produces sarcosine metabolites
- buffers for maintaining strong alkalinity and AHMT lysate that functions as a color source by reacting with formaldehyde produced by oxidizing sarcosine
- AHMT lysate that functions as a color source by reacting with formaldehyde produced by oxidizing sarcosine
- sarcosine oxidase that produces sarcosine metabolites, buffers that maintain strong alkalinity, and sarcocin are oxidized to MBTH lysate that functions as a color source by reacting with formaldehyde produced by oxidation.
- a method for preparing a prostate cancer diagnostic test paper prepared by dipping and drying a cellulose test paper.
- a water-soluble polymer fixture to allow the addition reagents to be fixed; It is preferable to further include.
- EDTA Ethylenediaminetetraacetic acid
- the concentration of sarcosine oxidase is preferably in the range of 200 ⁇ 500 unit / dL.
- the buffer is preferably 1.0 to 2.0 molarity, pH 9.0 to 12.5 range.
- the lysate further contains tatrazine in order to increase the color development of the color source.
- a prostate cancer diagnostic test paper using a peroxide, a sarcosine metabolite, a preparation method thereof, and a prostate cancer diagnostic method using the same are sarcosine oxidases that produce sarcosine metabolites. ; Peroxide colorants that function as colorants by reacting with peroxides in the sarcosine metabolite; And peroxidase, which functions as a catalyst; It provides a prostate cancer diagnostic test paper comprising a.
- the peroxide color source 3,3'-diaminobenzidine (3,3'-diaminobenzidine); 3,3 ', 5,5'-tetramethylbenzidine (3,3', 5,5'-tetramethylbenzidine); 1.4-diaminobenzene (1,4-diaminobenzene); 1,2-dihydroxybenzene; 4-chloronapthol; 3-amino-9-ethylcarbazole; 2,7'-diaminofluorene; N, N'-dimethylethylenediamine; N, N'-bis- (4-aminophenyl) -1,3-xylenediamine (N, N'-bis- (4-aminophenyl) -1,3-xylylenediamine); It is more preferable that it is at least one of them.
- a water-soluble polymer fixture to allow the addition reagents to be fixed; It is preferable to further include.
- EDTA Ethylenediaminetetraacetic Acid
- EDTA Ethylenediaminetetraacetic Acid
- the method for producing prostate cancer diagnostic test paper which is characterized by dissolving sarcosine oxidase and peroxidase in a buffer maintained at a pH of 7.5 to 10.0, immersing the cellulose test paper and then drying. Is provided.
- the concentration of the sarcosine oxidase is more preferably in the range of 200 ⁇ 500 unit / dL.
- the lysate preferably further comprises a water-soluble polymer fixture for fixing the reagents.
- the lysate further contains a dye in order to increase the color development of the color source.
- the lysate preferably further comprises EDTA for chelation of the metal ion in order to prevent the inhibition of the activity of sarcosine oxidase by the metal ion.
- the prostate cancer diagnostic test paper using formaldehyde, a sarcosine metabolite according to the present invention, and the prostate cancer diagnostic method using the same have the same expertise as conventional HPLC method and spectrophotometer method in qualitative and quantifying sarcosine in urine. After chemical reactions such as mixing samples and reagents in an in-house laboratory, it is possible to use them as diagnostic indicators of prostate cancer simply without the need for specialized personnel and expensive equipment, such as analyzing them using HPCL or spectrophotometer. There is.
- FIG. 1 is a block diagram showing the appearance of a test paper according to embodiments of the present invention
- Figure 2 is a change in the activity of sarcosine oxidase according to the pH according to the first embodiment of the present invention.
- 3 and 4 are photographs for explaining the experimental results for the implementation of the first embodiment of the present invention and a diagram illustrating them.
- FIG. 6 Mi 7 is a photograph for explaining the experimental results for the implementation of the second embodiment of the present invention and a diagram illustrating the same.
- first and second may be used to describe various components, but the components should not be limited by the terms. The terms are used only for the purpose of distinguishing one component from another.
- the first component may be referred to as the second component, and similarly, the second component may also be referred to as the first component.
- all terms used herein, including technical or scientific terms have the same meaning as commonly understood by one of ordinary skill in the art. Terms such as those defined in the commonly used dictionaries should be construed as having meanings consistent with the meanings in the context of the related art and shall not be construed in ideal or excessively formal meanings unless expressly defined in this application. Do not.
- a prostate cancer diagnostic test paper using formaldehyde, a sarcosine metabolite according to the first embodiment of the present invention, and a prostate cancer diagnostic method using the same can easily perform diagnostic indicators of prostate cancer without expensive equipment and specialists. To be.
- Sarcosine is metabolized to Glycine, Peroxide (H 2 O 2 ) and Formaldehyde by Sarcosine Oxidase. By doing so, it is possible to calculate the concentration of sarcosine, which can be used as a diagnostic indicator of prostate cancer.
- This metabolic process is represented by the following [Formula 1].
- Sarcosine generates peroxide and formaldehyde in proportion to the concentration of sarcosine by sarcosine oxidase as shown in [Formula 1].
- Factors affecting the activity of sarcosine oxidase at this time include the pH and concentration of the buffer (Buffer Solution), the reaction temperature and the like.
- the reaction temperature at this time is sufficient if it is room temperature, the concentration of the buffer is approximately 1 to 2 molar concentration, the pH is preferably 8 to 9.5.
- Tris Tris, Phosphate, Citrate, Borate, and the like can be used as the buffer.
- Formaldehyde produced by sarcosine oxidase is 4-amino-3-hydrazino-5-mercapto-1,2,4-triazole as described in [Formula 2] (4-Amino-3-hydrazino- 5-mercapto-1,2,4-triazole; hereinafter referred to as AHMT) and N-methylbenzothiazolinone-2-hydrazone (hereinafter referred to as [Formula 3]) below MBTH
- AHMT 4-Amino-3-hydrazino- 5-mercapto-1,2,4-triazole
- [Formula 3] N-methylbenzothiazolinone-2-hydrazone
- the yellow color may be used to make the background color yellow, and an additional method may be used in which the color tends to be colored green or cyan so that the color tends to be more dull than blue. have.
- an additional method may be used in which the color tends to be colored green or cyan so that the color tends to be more dull than blue.
- tatrazine was used in this embodiment.
- a water-soluble polymer fixture may be added to allow the surfactant to be easily absorbed into the test paper and the reagents added to the cellulose test paper.
- the reaction is dependent on the pH, as shown in [Fig. 2] should be at least pH 9.0 or more to the reaction as shown in [Formula 2] to form a purple complex.
- the reaction as described in [Formula 3] proceeds to form a blue complex to be visually confirmed through the color change of the test paper.
- a solution of 1.5 mol of borate-sodium hydroxide pH 9.5-12 is prepared and used as a buffer in consideration of the test paper being immersed in the sample under severe pH conditions.
- borate-sodium hydroxide was used, but other buffer solutions may be used if strong alkalinity is sufficiently maintained. If the pH is lower than this, no reaction occurs. If the pH is higher than this, the test paper is destroyed due to the strong alkalinity of the solution when immersing the cellulose test paper.
- the activity of sarcosine oxidase is greatly influenced by metal ions, and since metal ions are inevitably present in the sample, chelation of the sarcosine oxidase reduces the activity of sarcosine oxidase by metal ions.
- add 0.01 to 0.02 g / dL of EDTA 0.01 to 0.02 g / dL of EDTA.
- the addition amount is insufficient to remove the metal ions, on the contrary, when the amount is large, the color reaction is lowered.
- EDTA4NA was used, but other materials that can chelate metal ions may be used.
- FIG. 3 is an experimental result for diagnosing prostate cancer using test paper prepared by the above method
- FIG. 4 is a diagram illustrating the prostate cancer.
- FIG. 4 shows white, pale orange, yellow or purple on the basis of one strip.
- the top white is a white test paper that has not been treated to determine the background color of the sample; for the second pale orange test paper, the test paper is used to check the degree of dilution of the urine.
- It is a photograph of sarcosine detection reaction using formaldehyde using AHMT at Negative, 1000, 2000, 4000 nM from the left. (Test paper changed to yellow and purple)
- Prostate cancer diagnostic test paper using peroxide, a sarcosine metabolite according to a second embodiment of the present invention, and a prostate cancer diagnostic method using the same it is possible to easily perform the diagnostic indicators of prostate cancer without expensive equipment and professional personnel. .
- sarcosine is metabolized by Glycine, Peroxide (H 2 O 2 ) and Formaldehyde by Sarcosine Oxidase.
- Glycine Peroxide (H 2 O 2 )
- Formaldehyde by Sarcosine Oxidase.
- Sarcosine generates peroxide and formaldehyde in proportion to the concentration of sarcosine by sarcosine oxidase as shown in [Formula 4].
- Factors affecting the activity of sarcosine oxidase at this time include the pH and concentration of the buffer (Buffer Solution), the reaction temperature and the like.
- the reaction temperature at this time is sufficient if it is room temperature, the concentration of the buffer is approximately 1 to 2 molar concentration, the pH is preferably 8 to 9.5.
- Tris Tris, Phosphate, Citrate, Borate, and the like can be used as the buffer.
- Peroxidase catalyzing the peroxide dehydrogenation reaction generated by sarcosine oxidase is represented in the formula [6] specifically, the activity of about 50 to 80% of the sarcosine oxidase It is enough to add the amount.
- the yellow color may be used to make the background color yellow, and an additional method may be used in which the color development tends to be green or cyan instead of blue.
- a surfactant may be added to allow urine to be readily absorbed into the test paper, and a fixture (usually using a water soluble polymer) may be added to allow the addition reagents to be fixed to the cellulose test paper.
- the dipping solution must be prepared in two separate portions.
- the concentration of the buffer is 0.05 ⁇ 0.1 molar concentration, pH 7.5 ⁇ 8.5 is sufficient.
- the test paper prepared by the colorimetric test paper method is immersed in the sample and exposed to the acidic pH of the sample.
- the buffer of the primary solution is used to prepare a solution of borate-sodium hydroxide pH 8.0-9.5, 1.0 to 2.0 molarity.
- an excess enzyme of 200-500 unit / dL of sarcosine oxidase should be added in consideration of the diminished enzyme activity when the test paper is immersed in the preparation solution and then thermally dried. If the amount of sarcosine oxidase is small at this time, the activity of the enzyme decreases during the drying process of the test paper, so that it may not have sufficient reactivity. If the amount is large, it may cause not only an increase in cost but also natural discoloration.
- a water-soluble polymer polyvinylpyrrolidine 1.0-2.0 g / dL, is added so that the reagents to be added to the cellulose test paper can be fixed.When the addition amount is small, the reagent is not fixed to the test paper so that the reagents are dipped into the sample. This elution results in color contamination, and high amounts can interfere with the absorption of the sample, even with water-soluble polymers.
- the activity of sarcosine oxidase is greatly influenced by metal ions. If excess metal ions are present in the sample, chelating them and removing them reduces the activity of sarcosine oxidase by metal ions. To prevent this, add 0.01 to 0.02 g / dL of EDTA. In other words, EDTA is to act as a metal adsorbent, so that the enzyme is activated well. In this embodiment, EDTA4NA was used, but other materials that can chelate metal ions may be used. On the other hand, in the case of EDTA, the addition amount is insufficient to remove the metal ions, on the contrary, when the amount is large, the color reaction is lowered.
- the cellulose test paper is immersed, and the excess reagent is dried for 30 minutes at 70 to 80 ° C after removal.
- the secondary solution is based on 0.5-1.0 molar concentration of borate-hydrochloric acid pH 6.0-7.0 buffer so that the peroxidase can be immobilized safely. 100-200 unit / dL, 3,3 ', 5,5'-tetramethylbenzidine Dissolve 20 mmol (mM) concentration. At this time, if the amount of reagent is small, there is no color difference in medium and high concentration samples. On the contrary, the amount of reagent is discolored in natural state, resulting in deterioration or false positive of the product.
- the first test solution is immersed and dried again in the second solution and dried for 30 minutes at 70 ⁇ 80 °C.
- FIG. 6 is an experimental result for diagnosing prostate cancer using test paper prepared by the above method
- FIG. 7 is an illustrated view for clearly expressing this, from left to right, Negative, 1000, 2000, 4000 nM It is a photograph of sarcosine detection reaction using peroxidase when 3,3 ', 5,5'-tetramethylbenzidine is used.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (22)
- 사르코신 대사산물을 생성하는 사르코신 산화효소(Sarcosine Oxidase); 및사르코신이 산화되어 생성된 포름알데히드와 반응하여 색원체로 기능하는 4-아미노-3-하이드라지노-5-머캅토-1,2,4-트리아졸(AHMT : 4-Amino-3-hydrazino-5-mercapto-1,2,4-triazole); 을 포함하는 것을 특징으로 하는 전립선암 진단 시험지.
- 사르코신 대사산물을 생성하는 사르코신 산화효소(Sarcosine Oxidase); 및사르코신이 산화되어 생성된 포름알데히드와 반응하여 색원체로 기능하는 엔-메칠벤조티아조리온-2-히디드라즈온(MBTH : N-methylbenzothiszolinone-2-hydrazone); 을 포함하는 것을 특징으로 하는 전립선암 진단 시험지.
- 제 1 항 또는 제 2 항 중 어느 한 항에 있어서,첨가 시약들이 고정될 수 있도록 하는 수용성 고분자 고정체; 를 더 포함하는 것을 특징으로 하는 전립선암 진단 시험지.
- 제 1 항 또는 제 2 항 중 어느 한 항에 있어서,금속이온에 의한 사르코신 산화효소의 활성도 저해 방지를 위하여 상기 금속이온을 킬레이트화시켜 제거하는 EDTA(Ethylenediaminetetraacetic Acid); 를 더 포함하는 것을 특징으로 하는 전립선암 진단 시험지.
- 전립선암 진단 시험지 제조 방법에 있어서,사르코신 대사산물을 생성하는 사르코신 산화효소, 강알칼리성을 유지시키는 완충액, 사르코신이 산화되어 생성된 포름알데히드와 반응하여 색원체로 기능하는 AHMT 용해물에 셀룰로오즈 시험지를 침지시킨 후 건조시켜 제조하는 전립선암 진단 시험지 제조 방법.
- 전립선암 진단 시험지 제조 방법에 있어서,사르코신 대사산물을 생성하는 사르코신 산화효소, 강알칼리성을 유지시키는 완충액, 사르코신이 산화되어 생성된 포름알데히드와 반응하여 색원체로 기능하는 MBTH 용해물에 셀룰로오즈 시험지를 침지시킨 후 건조시켜 제조하는 전립선암 진단 시험지 제조 방법.
- 제 5 항 또는 제 6 항 중 어느 한 항에 있어서,상기 사르코신 산화효소의 농도는 200 ~ 500 unit/dL의 범위인 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 5 항 또는 제 6 항 중 어느 한 항에 있어서,상기 완충액은 1.0 ~ 2.0 몰농도이고, pH 9.0 ~ 12.5 범위인 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 5 항 또는 제 6 항 중 어느 한 항에 있어서,상기 용해물은 시약들을 고정시키는 수용성 고분자 고정체가 더 포함되어 있는 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 5 항 또는 제 6 항 중 어느 한 항에 있어서,상기 용해물은 색원체의 발색을 도드라지게 하기 위하여 타트라진이 더 포함되어 있는 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 5 항 또는 제 6 항 중 어느 한 항에 있어서,상기 용해물은 금속이온에 의한 사르코신 산화효소의 활성도 저해 방지를 위하여 상기 금속이온을 킬레이트화시키는 EDTA가 더 포함되어 있는 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 1 항 내지 제 6 항 중 어느 한 항에 의한 전립선암 진단 시험지로 전립선암을 진단하는 방법.
- 사르코신 대사산물을 생성하는 사르코신 산화효소(Sarcosine Oxidase);상기 사르코신 대사산물 중 과산화물과 반응하여 색원체로 기능하는 과산화물 색원체; 및촉매제의 기능을 하는 과산화효소(Peroxidase); 를 포함하는 것을 특징으로 하는 전립선암 진단 시험지.
- 제 13항에 있어서,상기 과산화물 색원체는,3,3'-다이아미노벤지딘(3,3'-diaminobenzidine); 3,3',5,5'-테트라메칠벤지딘(3,3',5,5'-tetramethylbenzidine); 1.4-다이아미노벤젠 (1,4-diaminobenzene); 1,2-다이하이드록시벤젠(1,2-dihydroxybenzene); 4-클로로나프톨(4-chloronapthol); 3-아미노-9-에틸카바졸(3-amino-9-ethylcarbazole); 2,7'-다이아미노플로렌(2,7'-diaminofluorene); 엔,엔'-다이메칠에틸렌다이아민(N,N'-dimethylethylenediamine); 엔,엔'-비스-(4-아미노페닐)-1,3-자이렌다이아민(N,N'-bis-(4-aminophenyl)-1,3-xylylenediamine); 중 어느 하나 이상인 것을 특징으로 하는 전립선암 진단 시험지
- 제 13 항에 있어서,첨가 시약들이 고정될 수 있도록 하는 수용성 고분자 고정체; 를 더 포함하는 것을 특징으로 하는 전립선암 진단 시험지.
- 제 13 항에 있어서,금속이온에 의한 사르코신 산화효소의 활성도 저해 방지를 위하여 상기 금속이온을 킬레이트화시켜 제거하는 EDTA(Ethylenediaminetetraacetic Acid); 를 포함하는 것을 특징으로 하는 전립선암 진단 시험지.
- 전립선암 진단 시험지 제조 방법에 있어서,사르코신 산화효소 및 과산화효소를 pH 7.5 ~ 10.0 범위를 유지하는 완충액에 용해하여 셀룰로오즈 시험지를 침지시킨 후 건조하는 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 17 항에 있어서,상기 사르코신 산화효소의 농도는 200 ~ 500 unit/dL의 범위인 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 17 항에 있어서,상기 용해물은 시약들을 고정시키는 수용성 고분자 고정체가 더 포함되어 있는 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 17 항에 있어서,상기 용해물은 색원체의 발색을 도드라지게 하기 위하여 염료가 더 포함되어 있는 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 17 항에 있어서,상기 용해물은 금속이온에 의한 사르코신 산화효소의 활성도 저해 방지를 위하여 상기 금속이온을 킬레이트화시키는 EDTA가 더 포함되어 있는 것을 특징으로 하는 전립선암 진단 시험지 제조 방법.
- 제 13 항 내지 제 16 항 중 어느 한 항에 의한 전립선암 진단 시험지로 전립선암을 진단하는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480051799.5A CN105555962A (zh) | 2013-10-04 | 2014-09-30 | 利用肌氨酸代谢产物中的甲醛或过氧化物的前列腺癌诊断试纸,其制造方法及利用其的前列腺癌诊断方法 |
US15/022,102 US20160222432A1 (en) | 2013-10-04 | 2014-09-30 | Test strip using formaldehyde or peroxide, from among sarcosine metabolites, for diagnosing prostate cancer, and method for diagnosing prostate cancer using same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0118446 | 2013-10-04 | ||
KR1020130118446A KR101838133B1 (ko) | 2013-10-04 | 2013-10-04 | 사르코신 대사산물 중 포름알데히드를 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법 |
KR10-2013-0121327 | 2013-10-11 | ||
KR1020130121327A KR101955430B1 (ko) | 2013-10-11 | 2013-10-11 | 사르코신 대사산물 중 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015050366A1 true WO2015050366A1 (ko) | 2015-04-09 |
Family
ID=52778913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/009215 WO2015050366A1 (ko) | 2013-10-04 | 2014-09-30 | 사르코신 대사산물 중 포름알데히드 또는 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단 방법 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160222432A1 (ko) |
CN (1) | CN105555962A (ko) |
WO (1) | WO2015050366A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107759437A (zh) * | 2017-10-18 | 2018-03-06 | 云南省玉溪市云溪香精香料有限责任公司 | 一种处理吐纳麝香粗品中间体中的游离氯化氢的方法 |
US11384381B2 (en) * | 2016-07-13 | 2022-07-12 | Kikkoman Corporation | Reaction accelerating agent |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107162994B (zh) * | 2017-04-24 | 2020-08-14 | 浙江师范大学行知学院 | 一种4h-1,2,4-三唑-3-硫醇衍生物及其制备方法与应用 |
CZ2017272A3 (cs) * | 2017-05-16 | 2018-11-28 | Prevention Medicals s.r.o. | Diagnostický proužek pro stanovení množství sarkosinu, kreatininu a peroxidu vodíku v biologickém nebo environmentálním vzorku |
CN110108700A (zh) * | 2019-04-18 | 2019-08-09 | 迪瑞医疗科技股份有限公司 | 一种多胺检测试剂、多胺检测干化学试纸条及其制备方法 |
WO2024061281A1 (zh) * | 2022-09-22 | 2024-03-28 | 宁波大学附属第一医院 | 前列腺癌检测试剂盒及其应用、膀胱癌检测试剂盒及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010537170A (ja) * | 2007-08-16 | 2010-12-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 前立腺癌の代謝プロファイリング法 |
KR20120124320A (ko) * | 2011-05-03 | 2012-11-13 | (주)에스에이치제약 | 인간의 소변을 검체로 이용하여 전립선암을 진단하는 진단키트 및 그 제조방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60135865A (ja) * | 1983-12-26 | 1985-07-19 | Kobayashi Seiyaku Kk | クレアチニン及びクレアチンの同時定量方法並びにそのキツト |
US5804452A (en) * | 1995-04-27 | 1998-09-08 | Quidel Corporation | One step urine creatinine assays |
AU2003231163A1 (en) * | 2002-05-01 | 2003-11-17 | Polymer Technology Systems, Inc. | Test strip and method for determining concentration of creatinine in a body fluid |
-
2014
- 2014-09-30 CN CN201480051799.5A patent/CN105555962A/zh active Pending
- 2014-09-30 US US15/022,102 patent/US20160222432A1/en not_active Abandoned
- 2014-09-30 WO PCT/KR2014/009215 patent/WO2015050366A1/ko active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010537170A (ja) * | 2007-08-16 | 2010-12-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 前立腺癌の代謝プロファイリング法 |
KR20120124320A (ko) * | 2011-05-03 | 2012-11-13 | (주)에스에이치제약 | 인간의 소변을 검체로 이용하여 전립선암을 진단하는 진단키트 및 그 제조방법 |
Non-Patent Citations (3)
Title |
---|
BAUM ET AL.: "Sarcosine as a potential prostate cancer biomarker and therapeutic target", CANCER BIOLOGY & THERAPY, vol. 9, no. 5, 2010, pages 341 - 342 * |
BURTON ET AL.: "A novel enzymatic technique for determination of sarcosine in urine samples", ANALYTICAL METHODS, vol. 4, no. 1, 2012, pages 141 - 146 * |
SALTHAMMER ET AL.: "Formaldehyde in the indoor environment", CHEMICAL REVIEWS, vol. 110, no. 4, 2010, pages 2536 - 2572 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11384381B2 (en) * | 2016-07-13 | 2022-07-12 | Kikkoman Corporation | Reaction accelerating agent |
CN107759437A (zh) * | 2017-10-18 | 2018-03-06 | 云南省玉溪市云溪香精香料有限责任公司 | 一种处理吐纳麝香粗品中间体中的游离氯化氢的方法 |
Also Published As
Publication number | Publication date |
---|---|
US20160222432A1 (en) | 2016-08-04 |
CN105555962A (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015050366A1 (ko) | 사르코신 대사산물 중 포름알데히드 또는 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단 방법 | |
CN105388146B (zh) | 一种同时检测尿液中钠、肌酐和微量白蛋白的试剂盒 | |
US6121050A (en) | Analyte detection systems | |
US5516700A (en) | Automated urinalysis method | |
CS231174B2 (en) | Method of elimininating of disturbung effect of askorbic acid in tested system in proving oxidative-reducing reaction and diagnostic means to perform the method | |
WO2010010881A1 (ja) | 溶血させた全血を用いる血中成分の測定方法及びそのキット | |
EP0113103A1 (en) | Inhibition of reduction activities of leukocytes | |
CN112014389A (zh) | 一种抗坏血酸干扰的尿潜血检测试纸及其制备方法 | |
KR101838133B1 (ko) | 사르코신 대사산물 중 포름알데히드를 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법 | |
US5885789A (en) | Solution-based assay for peroxidatively-active substances in bodily fluids | |
US20220128540A1 (en) | Assays and methods for diagnosing substance use disorder | |
US20120077278A1 (en) | Methods and kits for detecting, diagnosing and monitoring diseases | |
KR101955430B1 (ko) | 사르코신 대사산물 중 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법 | |
CN110398586B (zh) | 果糖胺测定试剂盒 | |
JPWO2006030866A1 (ja) | 尿酸の定量方法 | |
JP2014174057A (ja) | ヘモグロビンの高感度測定法と試薬 | |
CN113376150A (zh) | 一种尿液微量白蛋白干化学检测试纸及其制备方法 | |
CN110220896A (zh) | 一种毒物定性半定量检测试剂盒及毒物定性半定量方法 | |
WO2019075471A2 (en) | BIOSENSOR DETECTING GLUCOSE LEVELS OF FREE GLUCOSE, HEMOGLOBIN A1C AND GLYCATED BLOOD PROTEINS IN ONE SAME BLOOD SAMPLE | |
US5733785A (en) | Automated urinalysis method for detecting blood in urine | |
Skjold et al. | New dip-and-read test for determining leukocytes in urine. | |
JPS592700A (ja) | 総ポリアミンの測定方法 | |
US10690597B2 (en) | Device and method for detection of humidity-compromised urine test strips | |
EP0243125B1 (en) | Method of measuring phenol and alpha-naphthol, and method of measuring the activity of enzymes | |
US5736408A (en) | Method for the detection of urobilinogen in urine on an automated analyzer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480051799.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14850889 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15022102 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14850889 Country of ref document: EP Kind code of ref document: A1 |